Results 181 to 190 of about 57,115 (246)

Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. [PDF]

Cancer Res
Woo SM, Kang JH, Choi W, Lee H, Jang H, Sim SH, Chun JW, Koh EB, Kim C, Ham W, Hong W, Kang M, Park J, Han S, Kim JW, Lee EW, Lee WJ, Kim SY.   +17 more
europepmc   +1 more source

NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. [PDF]

ESMO Gastrointest Oncol
Ueno M, Ikezawa K, Komatsu Y, Nagano H, Hisano T, Terashima T, Nio K, Morizane C, Shimizu S, Ozaka M, Ohyama H, Otsuru T, Sudo K, Mizuno N, Daniel C, Martín-Fernández L, Amellal N, Bernard K, Sasaki M.   +18 more
europepmc   +1 more source

The phase I trial of preoperative short-course chemoradiotherapy with S-1/irinotecan and short-course radiation in locally advanced lower rectal cancer (SHOWTIME study). [PDF]

Radiat Oncol
Kojo K, Tanaka T, Yamanashi T, Miura H, Yokoi K, Kojima K, Yokota K, Kawakami S, Ishiyama H, Yamashita K, Kumamoto Y, Hiki N, Sato T, Naitoh T.   +13 more
europepmc   +1 more source

Irinotecan [PDF]

, 2020
openaire   +1 more source

Patient-Derived Organoid and Single-Cell Multiomics Reveal Evolution Driven by CEACAM6/KRT19-Mediated Heterogeneity. [PDF]

FASEB J
Jing C, Wang Z, Cao H, Zhang Y, Huang Y, Yu Y, Li B, Ma R.   +7 more
europepmc   +1 more source

Extending the utility of anti-EGFR therapy in metastatic colorectal cancer. [PDF]

J Gastrointest Oncol
Cann C, Vijayvergia N.
europepmc   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source

Recurrent Mandibular Ewing sarcoma in an 11-year-old boy: a rare pediatric case and review of the literature. [PDF]

J Med Case Rep
Nourbakhsh SMK, Shirkhoda M, Jangjoo T.
europepmc   +1 more source

Impact of <i>UGT1A1*28</i> polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. [PDF]

Future Oncol
Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A.   +10 more
europepmc   +1 more source

Adaptive Surgical Decision-Making for Synchronous Metastatic Pancreatic Cancer and Early Breast Cancer with a BRCA1 Pathogenic Variant: A Case Report. [PDF]

Surg Case Rep
Akahori T, Yokotani T, Yoshizawa A, Uchiyama T, Yamaguchi R, Sho M.   +5 more
europepmc   +1 more source